Floatz logo

18F-ASIS

Thymus Neoplasms

National Cancer Institute (NCI)Phase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Thymus Neoplasms cohort.

Asset / SponsorPhaseRating
18f-flt
National Cancer Institute (NCI)
Phase 2CCC
Tnhyp217 Car T Cells
National Cancer Institute (NCI)
Phase 1CC
Fludarabine
National Cancer Institute (NCI)
Phase 1CC
Cyclophosphamide
National Cancer Institute (NCI)
Phase 1CC
Mithramycin
National Cancer Institute (NCI)
Phase 1/2D

Same molecule, other indications

18F-ASIS is also rated in:

Inflammatory Demyelinating DiseaseDormant
CCC
Indicative ·
53 / 100
View asset →
Non-small Cell Lung CancerDormant
CCC
Indicative ·
50 / 100
View asset →
Prostate CancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →